Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/07/2018|
|Rapid review completed||27/07/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||01/08/2018|